BIOLINERX Ltd/S (NASDAQ:BLRX) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.06) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.06), Morningstar.com reports.
Shares of BLRX traded down $0.01 during trading hours on Friday, hitting $0.70. 391,694 shares of the stock were exchanged, compared to its average volume of 1,728,884. BIOLINERX Ltd/S has a 12-month low of $0.67 and a 12-month high of $1.84. The stock has a market capitalization of $78.77 million, a price-to-earnings ratio of -2.59 and a beta of 0.87.
A hedge fund recently bought a new stake in BIOLINERX Ltd/S stock. Fosun International Ltd purchased a new position in shares of BIOLINERX Ltd/S (NASDAQ:BLRX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,357,415 shares of the biotechnology company’s stock, valued at approximately $1,412,000. Fosun International Ltd owned approximately 1.27% of BIOLINERX Ltd/S as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 34.69% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3928844/biolinerx-ltd-s-blrx-posts-quarterly-earnings-results-meets-expectations.html.
BIOLINERX Ltd/S Company Profile
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Read More: Why does a company issue an IPO?
Receive News & Ratings for BIOLINERX Ltd/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX Ltd/S and related companies with MarketBeat.com's FREE daily email newsletter.